BioDelivery: Good Time to Buy? Print E-mail
By Vinny Cassano   
Saturday, 19 February 2011 00:00

Earlier this week, BioDelivery Sciences (NSDAQ:BDSI) announced that the ongoing BEMA Buprenorphine Phase III trial is more than 50% enrolled and is expected to be completed on schedule.



Buprenorphine is an attractive option for development because of its potent analgesic properties, its differentiating characteristics from other opioids, and its DEA Schedule III designation, which means there is less addiction potential than Schedule II products.  According to the company, opioid analgesic sales in the U.S. are in excess of $10 billion and growing, and BDSI believes that BEMA Buprenorphine has the potential to exceed $500 million in peak annual sales.

The trial, measuring BEMA Bup for effectiveness in treating chronic pain, began in December of last year and is scheduled to wrap-up later this year, with an expected NDA filing to take place during the first half of 2011.

BioDelivery also has Onsolis on the market in both the US and Canadian markets for the treatment of breakthrough cancer pain.  Onsolis sales have currently been hindered by an ongoing REMS issue, but both BDSI and partner Meda have been making headway in discussions with the FDA and it's expected that the ordeal will draw to a close later this year.

With a novel drug delivery system and multiple products in the pipeline, BioDelivery is still one with significant growth potential over the long term.  Looks like the low-$3 range is the time to add shares.

As pointed out on Seeking Alpha recently, BDSI is favorably reviewed by analysts with a fairly strong buy rating and a forecasted upside close to double the current price.

Vinny also authors the popular stock investing blog, VFC's Stock House.


Disclosure:  Long BDSI



"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus
 

Newsletter